Masters of Immunology
Cancer Immunol Res September 1 2013 1 (3) 145-149; DOI:10.1158/2326-6066.CIR-13-0102
Pico de Coaña and colleagues analyzed peripheral blood from patients undergoing ipilimumab treatment at weeks 0, 3, and 9 and found a sequential decrease in the frequencies of granulocytic MDSC and arginase1-producing CD3-negative cells. At week 9, they found a lower number of Tregs and reduced PD-1 surface expression in CD3-positive cells.
Regulatory T cells play a central role in tumor escape from immune-mediated rejection. Using a bispecific antibody targeting the tumor-specific mutation of the EGF receptor, EGFRvIII, Choi and colleagues describe a new mechanism they identified by which regulatory T cells can be redirected to elicit potent antitumor activity.
Simpkins and colleagues found that the combination of FDA-approved dose and schedule of pegylated liposomal doxorubicin (PLD) with human recombinant IL-18 (SB-485232) in patients with recurrent advanced ovarian cancer induced minimal toxicity across the IL-18 dose range studied and did not reach a maximum tolerated dose. The concomitant and repeat administration of PLD did not attenuate the immunostimulatory effects of IL-18, providing a rationale for a future phase II trial to further evaluate this combination regimen.
Yan and colleagues evaluated the efficacy of a synthetic, optimized, electroporation-delivered DNA vaccine targeting hTERT in overcoming tolerance and inducing hTERT-specific antitumor immunity in murine and nonhuman primate models.
Using sera from patients with colorectal cancer, Laske and colleagues identified a novel alternative HYDIN transcript from a testis-derived cDNA expression library with reactivity to patient IgG, and defined two HYDIN variants as novel tumor-associated antigens recognized by both antibodies and CD8 cytotoxic T cells.